GlassScriptPhysician profile
Upendra C Patel
NPI 1932103868
$2,932.72
in general payments reported to CMS, 2019-2025
35 companies · $18.31 in 2025
The $18.31 reported for 2025 was less than what a typical Internal Medicine provider received nationally (typical 2025 total: $156).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $1,497 · 2020: $896 · 2021: $243 · 2022: $142 · 2023: $135 · 2025: $18.31.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $153.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $153.27 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Astrazeneca Pharmaceuticals LP | $571.02 | 2019-2022 | |
| Glaxosmithkline, LLC. | $384.80 | 2019-2021 | |
| Boehringer Ingelheim Pharmaceuticals, INC. | $373.07 | 2019-2021 | |
| Grifols USA, LLC | $165.26 | 2019-2020 | |
| Mylan Specialty L.P. | $160.48 | 2019-2020 | |
| Amgen INC. | $146.04 | 2019-2022 | |
| Philips North America LLC | $111.76 | 2019-2021 | |
| Sunovion Pharmaceuticals INC. | $110.32 | 2019 | |
| Amarin Pharma, INC. | $75.62 | 2020-2021 | |
| Abbott Laboratories | $64.67 | 2019-2025 | Proclaim, Mitraclip |
| Shire North American Group INC | $63.98 | 2019 | |
| Takeda Pharmaceuticals U.S.A., INC. | $63.48 | 2020 | |
| Janssen Biotech, INC. | $57.17 | 2023 | Stelara, Simponi Aria, Remicade |
| Actelion Pharmaceuticals US, INC. | $54.03 | 2020 | |
| E.R. Squibb & Sons, L.L.C. | $50.68 | 2019 |
Show all 35 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Pfizer INC. | $49.90 | 2019-2021 | |
| Astellas Pharma US INC | $46.56 | 2021 | |
| Advanced Respiratory, INC | $42.37 | 2020 | |
| Electromed, INC. | $35.41 | 2019 | |
| Genzyme Corporation | $33.12 | 2019 | |
| United Therapeutics Corporation | $32.60 | 2021 | |
| Pulmonx Corporation | $30.44 | 2019-2020 | |
| Alnylam Pharmaceuticals INC. | $26.24 | 2023 | Givlaari |
| Insmed, INC. | $20.82 | 2019 | |
| Braintree Laboratories, INC. | $20.07 | 2023 | Suflave |
| Boston Scientific Corporation | $18.46 | 2023 | |
| Strongbridge US INC. | $16.63 | 2020 | |
| Regeneron Healthcare Solutions, INC. | $15.79 | 2019 | |
| Nevro Corp. | $14.87 | 2022 | |
| Gilead Sciences, INC. | $14.58 | 2019 | |
| Jazz Pharmaceuticals INC. | $13.69 | 2019 | |
| Kowa Pharmaceuticals America, INC. | $13.25 | 2020 | |
| Alfasigma USA, INC. | $12.17 | 2020 | |
| Circassia INC. | $11.73 | 2019 | |
| Merck Sharp & Dohme LLC | $11.64 | 2020 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Upendra Patel listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.